Peringatan Keamanan

Immune reconstitution inflammatory syndrome has been reported in one patient treated with TROGARZO in combination with other antiretrovirals. During the initial phase of combination antiretroviral therapies, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections, which may necessitate further evaluation and treatment FDA label.

Ibalizumab

DB12698

biotech approved investigational

Deskripsi

Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies L1558, L1554.

This drug was approved in March 2018 for the management of treatment-resistant HIV L1554. In October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.L43443,L43448

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of ibalizumab is 3 to 3.5 days on average. The half-life was estimated from a multiple-dose study evaluating weekly ibalizumab 10 mg/kg in 1 study arm and biweekly ibalizumab 25 mg/kg in another study arm, given via intravenous (IV) infusion in adults with HIV [L1555]. In one clinical trial, the elimination half-life increased from 2.7 to 64 hours as the dose increased from 0.3 to 25 mg/kg (0.01 to 0.9 times the approved recommended loading dose based on a 70 kg patient) [FDA label].
Volume Distribusi 4.8 L [FDA label]
Klirens (Clearance) Following single-dose administrations of ibalizumab-uiyk as 0.5 to 1.5-hour infusions, the area under the concentration-time curve increased in a greater than dose-proportional manner, clearance decreased from 9.54 to 0.36 mL/h/kg and elimination half-life increased from 2.7 to 64 hours as the dose increased from 0.3 to 25 mg/kg [FDA label].

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Metabolized by CD4 receptor internalization, ibalizumab has no significant impact on liver or kidney metabolism L1560.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

388 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Ibalizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Ibalizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Ibalizumab.
Estrone Estrone may increase the thrombogenic activities of Ibalizumab.
Estradiol Estradiol may increase the thrombogenic activities of Ibalizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Ibalizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Ibalizumab.
Mestranol Mestranol may increase the thrombogenic activities of Ibalizumab.
Estriol Estriol may increase the thrombogenic activities of Ibalizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Ibalizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Ibalizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Ibalizumab.
Tibolone Tibolone may increase the thrombogenic activities of Ibalizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ibalizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibalizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Ibalizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Ibalizumab.
Zeranol Zeranol may increase the thrombogenic activities of Ibalizumab.
Equol Equol may increase the thrombogenic activities of Ibalizumab.
Promestriene Promestriene may increase the thrombogenic activities of Ibalizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Ibalizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Ibalizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Ibalizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Ibalizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Ibalizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Ibalizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Ibalizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Ibalizumab.
Formononetin Formononetin may increase the thrombogenic activities of Ibalizumab.
Estetrol Estetrol may increase the thrombogenic activities of Ibalizumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibalizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibalizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibalizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibalizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Ibalizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibalizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibalizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Ibalizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ibalizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ibalizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibalizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ibalizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibalizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibalizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Ibalizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibalizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ibalizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibalizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibalizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Ibalizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Ibalizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibalizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibalizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ibalizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Ibalizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Ibalizumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ibalizumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Ibalizumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Ibalizumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Ibalizumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Ibalizumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Ibalizumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Ibalizumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Ibalizumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Ibalizumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Ibalizumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Ibalizumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Ibalizumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Ibalizumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Ibalizumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Ibalizumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Ibalizumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ibalizumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Ibalizumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Ibalizumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Ibalizumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Ibalizumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Ibalizumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Ibalizumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Ibalizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Ibalizumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Ibalizumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Ibalizumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Ibalizumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ibalizumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Ibalizumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Ibalizumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ibalizumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Ibalizumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Ibalizumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Ibalizumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Ibalizumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Ibalizumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Ibalizumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Ibalizumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Ibalizumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibalizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Ibalizumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Ibalizumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Ibalizumab.

Target Protein

C-C chemokine receptor type 5 CCR5
C-X-C chemokine receptor type 4 CXCR4
T-cell surface glycoprotein CD4 CD4

Referensi & Sumber

Artikel (PubMed)
  • PMID: 14722894
    Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V, Shanahan WR Jr: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis. 2004 Jan 15;189(2):286-91. Epub 2004 Jan 8.
  • PMID: 15180541
    Vermeire K, Schols D, Bell TW: CD4 down-modulating compounds with potent anti-HIV activity. Curr Pharm Des. 2004;10(15):1795-803.
  • PMID: 1888898
    Silberman SL, Goldman SJ, Mitchell DB, Tong AT, Rosenstein Y, Diamond DC, Finberg RW, Schreiber SL, Burakoff SJ: The interaction of CD4 with HIV-1 gp120. Semin Immunol. 1991 May;3(3):187-92.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Trogarzo
    Injection, solution, concentrate • 200 mg • Intravenous • EU
  • Trogarzo
    Injection, solution • 150 mg/1mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul